Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on WANDISCO PLC. We currently have 27 research reports from 4 professional analysts.
|23Feb17 07:00||RNS||Board Update|
|14Feb17 07:00||RNS||Notice of Results and Investor Presentation|
|18Jan17 16:40||RNS||Second Price Monitoring Extn|
|18Jan17 16:35||RNS||Price Monitoring Extension|
|16Jan17 07:00||RNS||Trading Update|
|30Dec16 07:00||RNS||Total Voting Rights|
|29Dec16 18:00||RNS||Director Dealings|
Frequency of research reports
Research reports on
Good progress across 2016
26 Jan 17
Following our notes on WANdisco in July and August (which focused on the IBM relationship and the Smart City deal) this brief comment summarises how the group has fared during 2016 and sets the scene for 2017. Alongside the major agreement with IBM, WANdisco produced encouraging interim results, announced significant contract wins and raised new equity. We highlight good arket engagement in the form of new contracts and note the record bookings and excellent progress towards its target of neutralising the monthly cash burn during Q4. The group ended 2016 with net cash of U$7.6 million, a strong order book and good sales pipeline.
23 Jan 17
WANdisco’s performance in H2 indicates that its investment in creating a platform for scalable growth is starting to reap returns. H2 bookings grew by 109%, costs reduced and in Q4 the company operated at close to cash-flow break even. The pipeline entering FY17 is strong and with three major tech partners – IBM, Oracle and Amazon – now generating sales, WANdisco looks exceptionally well placed to continue benefitting from the growth in cloud storage and big data.
Partners getting into gear
20 Dec 16
WANdisco’s $1m deal with a major automotive manufacturer via its OEM agreement with IBM is a positive indicator of the potential for this relationship to help drive an acceleration in growth. Add to this the November deal with Playtika through Amazon’s AWS Marketplace, WANdisco now has three major tech partners generating sales – IBM, Oracle and Amazon. Increasing sales volumes through these channels will be a key instrument for driving sustainable, strong scalable growth.
28 Feb 17
Avingtrans^ (AVG): Satisfactory interim results: small bolt-on acquisition (HOLD) |Seeing Machines* (SEE): Major contract win for Guardian (CORP) |Revolution Bars (RBG): Good H1 generates 3% FY forecast increase (BUY) |Victoria* (VCP): Upgrading forecasts post acquisition (CORP) |Wentworth Resources (WRL): Q4 2016 results and operational update (BUY)
27 Feb 17
accesso expects full year profitability to be ahead of expectations. We have upgraded our Adj. PBT by 7% to $14.7m. The performance was achieved despite accelerated investment in “product and infrastructure to support business and growth opportunities in geographies outside its traditional core markets”. We see clear blue sky opportunity in the Asia-Pacific Market. We increase our T/P from 1850p to 1900p and maintain our Outperform recommendation.
Hardman & Co Monthly: March 2017
01 Mar 17
Most major pharmaceutical companies have reported results for 2016 during the last few weeks, providing the opportunity to update our industry statistics. For an industry that requires a long investment cycle, decisions made many years ago have consequences on current financial performance. Being able to look at performance over 20 years highlights how strategic decisions have panned out.
N+1 Singer - NCC Group - Further issues in Assurance
22 Feb 17
NCC released a trading update yesterday afternoon highlighting further issues in its Assurance division. Sales growth has been lower than expected in all regions, resulting in a significant reduction in full year expectations. We have reduced our EPS forecasts by 25% in FY’17 and 22%/25% in FY’18/’19 respectively. Escrow continues to perform in line with expectations. In response to these issues the Board has announced a strategic review into all of the Assurance businesses. The results of the strategic review are expected to be announced at the FY results in July. With an extended period of uncertainty on the horizon we believe it will be hard for investors to gain confidence in NCC in the short term. That said we see fundamental value in the stock. Escrow is unaffected by this warning and remains an extremely high quality business, which we value at £353m in our SOTP. At the current share price this leaves Assurance valued at c.5x cal’17 EBITDA. While this appears to be an attractive multiple for a rare cybersecurity asset, we would like further clarity on the underlying nature of the current issues, hence our Hold recommendation. Our 138p target price assumes a 12x EBITDA multiple for Assurance but we apply a 20% discount to the group to account for the current uncertainty.
N+1 Singer - IDOX - Positive AGM statement
24 Feb 17
Idox issued a positive AGM statement, indicating a strong start to the year, building on the performance and organic and acquisitive growth of 2016. It recently secured significant contracts in healthcare and transport and is continuing to win across other segments. The order book and pipeline, combined with a stable outlook across all its markets, support our positive view on the stock. We make no changes to our estimates which were recently upgraded for FY’16 results and the accretive 6PM acquisition. We believe the current 11.2x cal’17 EV/EBITDA rating is undemanding given its scale, profitability and outlook.
N+1 Singer - Morning Song 23-02-2017
23 Feb 17
Genus (GNS LN) Interim results: R&D step-up, disappointing ABS performance | Howden Joinery Group (HWDN LN) Prelims and net cash better than expected but conditions weaken | Oxford Pharmascience Group (OXP LN) Encouraging interim OXPzero™ Ibuprofen exploratory PK data | StatPro Group (SOG LN) Increased majority shareholding in Infovest Consulting | Wilmington Group (WIL LN) Interims slightly ahead, move to focus on 3 verticals